m+Medelevator.RU
← Поиск публикаций
Journal of photochemistry and photobiology. B, Biology · 2025

Enhanced photodynamic therapy with riboflavin@ dual minerals doped hydroxyapatite nanoparticles: A promising in vitro approach for bladder cancer.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Wu Jinhua, Zong Dapeng, Li Fei

Аннотация

This research examines the efficacy of pure dual minerals (cerium and zinc) doped hydroxyapatite DHA and riboflavin (RFA)-coated DHA nanoparticles (NPs) (RFA@DHA NPs) in the treatment of bladder cancer. X-ray diffraction and Fourier-transform infrared spectroscopy validated the successful coating of RFA while preserving the core crystal structure of DHA. High-resolution transmission electron microscopy demonstrated the presence of spherical NPs, which exhibited a minor increase in size following RFA coating. Both NPs formulations exhibited significant concentration-dependent anticancer activity against T24 bladder cancer cells in the absence of UV irradiation, with RFA@DHA showing superior efficacy (IC50 values of 36.3 and 38.6 μg/mL, respectively). UV irradiation enhanced the effects of photodynamic therapy (PDT), with RFA@DHA demonstrating greater cytotoxicity (IC50 values of 27.9 and 32.6 μg/mL for RFA@DHA and pure DHA, respectively). Live/dead cell assays and nuclear condensation assays demonstrated that both NPs induced apoptosis in a time-dependent manner. The RFA coating mechanistically increased the production of reactive oxygen species (ROS) in both dark conditions and under UV irradiation, resulting in a notable disruption of the mitochondrial membrane potential, which is a critical event in the apoptotic pathway. The findings indicate that RFA-coated DHA NPs may serve as effective photosensitizers for bladder cancer therapy.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты